NR4A1 and breast carcinoma: In 1998, FDA approval was granted to Novartis for letrozole tablets (Femara®) as a second-line hormone based-chemotherapy for the treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or unknown breast cancer after primary anti-estrogen therapy [29].